ASCO 2021: Pembrolizumab plus axitinib continues to improve survival in kidney cancer
The KEYNOTE-426 study of the immune checkpoint inhibitor, pembrolizumab plus [...]
The KEYNOTE-426 study of the immune checkpoint inhibitor, pembrolizumab plus [...]
This Practice Update interview with Dr Monty Pal from City [...]
The Sottish Medicine Consortium (SMC) have issued a final decision to recommend [...]
To date, a reliable biomarker is yet to be discovered [...]
The Sottish Medicine Consortium (SMC) have issued a final decision to [...]
The National Institute for Health and Care Excellence (NICE) have issued [...]
KCSN are formal consultants to NICE and part of the [...]
Updated results from the KEYNOTE-426 study of pembrolizumab plus axitinib [...]
A recent study published in the journal In Vivo assessed [...]
Data from a recent phase I study of seleno-L-methionine in [...]